Crinetics Pharmaceuticals
CRNX
56 hedge funds and large institutions have $307M invested in Crinetics Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 7 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
12.56% more ownership
Funds ownership: 72.36% → 84.92% (+13%)
3% less funds holding
Funds holding: 58 → 56 (-2)
15% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 20
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
30% less capital invested
Capital invested by funds: $440M → $307M (-$133M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$68.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$7.17M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$3.57M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.1M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$10.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$850K |
| 4 |
Millennium Management
New York
|
-$453K |
| 5 |
Morgan Stanley
New York
|
-$311K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Ensign Peak Advisors
Salt Lake City,
Utah
| $16K | -$22.6K | -1,104 | -50% |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| $14K | – | – | – |
|
53
Canada Life
Winnipeg,
Manitoba, Canada
| $6K | – | – | – |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | -$4.22K | -206 | -43% |
|
|
AIC
55
Ameritas Investment Company
Lincoln,
Nebraska
| $4K | +$6.15K | +300 | New |
|
56
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | +$1.91K | +93 | New |
|
|
57
Point72 Asset Management
Stamford,
Connecticut
| – | -$850K | -33,865 | Closed |
|
|
58
Millennium Management
New York
| – | -$453K | -18,041 | Closed |
|
|
HF
59
HRT Financial
New York
| – | -$265K | -10,582 | Closed |
|
|
PP
60
Paloma Partners
Greenwich,
Connecticut
| – | -$210K | -8,369 | Closed |
|
61
Rockefeller Capital Management
New York
| – | -$177K | -7,066 | Closed |
|
|
CSS
62
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$118K | -4,700 | Closed |
|
63
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$35K | -1,402 | Closed |
|
CRNX Hedge Fund Activity: Q1 2020 in Review
56 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2020, worth a combined $307M — down 30% from $440M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CRNX and 5 opened new positions — a net loss of 2 holders — while 20 trimmed existing stakes and 17 added.
The largest buyer was Vivo Capital, opening a new position worth an estimated $68.1M. The largest seller was 5AM Venture Management, cutting an estimated $10.2M.
- 56 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2020, down from 58 in Q4 2019.
- Funds reported $307M of Crinetics Pharmaceuticals stock for Q1 2020, down 30% quarter-over-quarter.
- 5 funds opened new Crinetics Pharmaceuticals positions in Q1 2020 and 7 closed out, a net change of -2 holders.
- The largest Crinetics Pharmaceuticals buyer in Q1 2020 was Vivo Capital, an estimated $68.1M added.
- The largest Crinetics Pharmaceuticals seller in Q1 2020 was 5AM Venture Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2020.